Methylmalonyl-CoA mutase (2-methylmalonyl-CoA CoA-carbonylmutase, EC 5.4.99.2) is a mitochondrial enzyme whose deficiency in man leads to several biochemically and clinically heterogenous forms of methylmalonic acidemia. Intact fibroblasts from 21 patients with mutase apoenzyme deficiency have been pulse-labeled with [3H]leucine or [35S]methionine to determine how amounts of newly synthesized mutase recovered from these cells by immunoprecipitation compare with the amounts of steady-state crossreacting material previously determined. Ten lines (3 mutF, 7 muf), previously shown to have detectable steady-state crossreacting material, had amounts of newly synthesized mutase that varied from similar (7 lines) to considerably greater than (3 lines) the steady-state amounts. Of 11 lines that had no detectable steady-state crossreacting material, 6 had no detectable newly synthesized mutase, and 5 had amounts of mutase ranging from just detectable to almost half that of control. This result suggests that, at least for this latter group, one effect of the mutation in the mutase gene is to reduce the stability of the mutase protein. We examined fibroblasts from 48 patients with mutase apoenzyme deficiency to determine the sizes of the mature mutase subunit and the mutase precursor accumulated in the presence of the mitochondrial transport inhibitor rhodamine 6G. Of the 38 lines that had detectable newly synthesized mutase, only 2, lines 437 and 552, showed a pattern different from that generated by the normal precursor and mature subunits. Line 437 had two immunoprecipitable precursor proteins in the presence of rhodamine, each of which appeared to be transported and processed in the cells to produce two distinct mature proteins. Line 552 also had two anti-mutase reactive proteins in the presence of rhodamine, but each was smaller than the normal mature subunit and neither appeared to be proteolytically processed. The defect in line 552 is almost certainly an amino-terminal deletion that removes the leader peptide necessary for proper uptake and cleavage of the mutase precursor; this represents a clear example of a natural human mutation that interferes with mitochondrial transport of a protein.
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A number of enzymes whose deficiency leads to human metabolic disease are known to be localized to the mitochondria, including pyruvate dehydrogenase, ferrochetalase, and ornithine transcarbamoylase. Most mitochondrial enzymes are encoded in the nucleus and share a general scheme of biogenesis, which includes translation on free cytoplasmic polysomes as larger precursors, binding to mitochondria, energy-dependent translocation across one or both mitochondrial membranes, and, finally, specific proteolysis to mature-sized subunits and assembly into active enzymes (for recent reviews, see refs. 1 and 2). It has been shown that the amino-terminal leader sequences of the precursor proteins contain all of the information necessary to direct this complex series of events and that artificially produced mutations affecting the leader peptides can result in deficient uptake and processing (3, 4) . Thus, it is expected that there exist, among the naturally occurring mutations in these mitochondrial enzymes, some that affect targeting, translocation, or proteolysis. At this time, however, no such mutant proteins have been described. In large part, this may be because few studies have been carried out with this defect of biogenesis in mind. The most extensive to date, those of Ikeda and co-workers on fibroblast lines from 15 patients with isovaleryl-CoA dehydrogenase deficiency (5) and from 13 patients with medium chain acyl-CoA dehydrogenase deficiency (6), have failed to reveal an unequivocal defect in mitochondrial import of the precursors of these enzymes.
For some time, we have studied methylmalonyl-CoA mutase (2-methylmalonyl-CoA CoA-carbonylmutase, EC 5.4.99.2; "mutase") as a model mitochondrial enzyme and as a protein whose deficiency results in human disease. Mutase, the last enzyme in the propionate pathway of branched-chain amino acid and odd-chain fatty acid catabolism, is localized to the mitochondrial matrix and has been shown to follow the general scheme of mitochondrial uptake and processing outlined above, in vitro and in cultured cells (7) . Mutase is a dimer of identical 77.5-kDa subunits; the precursor is about 3-4 kDa larger.
Defects in the mutase apoenzyme are one cause of methylmalonic acidemia in man, comprising the mut complementation group, and are expressed in fibroblast cell lines derived from patients with this disease (8) . We have previously used our extensive collection oflines from such patients to identify two subgroups, those with (mut-) and those without (mut°) residual mutase activity, and to show that the mutF lines produce mutant enzymes with abnormal binding constants for cofactor, adenosylcobalamin (9). We have also quantitated by radioimmunoassay the amount of crossreacting mutase protein present in these cells under steady-state conditions (10 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
their Yale accession numbers. The fibroblasts were maintained in Eagle's minimal essential medium supplemented with 10% fetal bovine serum (MEM-E) in a 5% C02/95% air atmosphere, as before (10) . Prior to labeling, cells were subcultured in 10-cm dishes and grown to confluence in MEM-E. Lines that were grown in quantity for the preparation of mRNA were cultured in MEM-E in 850-cm2 roller bottles under a 5% CO2 atmosphere.
Radiolabeling (Amersham) essentially as described (7) . When the inhibitor rhodamine 6G (R6G) was used, it was added to a final concentration of 10 gg/ml 30 min prior to the addition of the labeled amino acid. After labeling for 60 min, the cells were harvested with 1 ml of immunoprecipitation buffer (150 mM NaCl/10 mM EDTA, pH 7.4/0.5% Triton X-100/0.25% NaDodSO4, plus 1% leucine or methionine, as appropriate) per dish. The cell extracts were combined and sonicated briefly and then centrifuged at 35,000 x g for 20 min. Anti-mutase antiserum (8 ,ul) was added to the supernatant, and the mixture was incubated overnight. The antigenantibody complexes were recovered with Staphylococcus aureus cells, washed, and eluted as before (7).
Isolation of mRNA and in Vitro Translation. Ten to 12 roller bottles (850 cm2, Falcon) containing confluent monolayers of each cell line were harvested by trypsinization and stored frozen at -70°C until used. Total RNA was prepared as described by Chirgwin et al. (11), except that the frozen cells were broken by sonication. Poly(A)+ RNA (100 ,ug) was isolated and fractionated on linear sucrose gradients as in Skovby et al. (12) . An aliquot (5 ,ul) of each fraction was used to direct in vitro translation as above and immunoprecipitated to determine the peak mutase mRNA fractions. Optimal RNA concentrations for translation were then determined for each RNA preparation. Gel Electrophoresis and Fluorography. Polyacrylamide gel electrophoresis was carried out on the immunoprecipitated material essentially as described (7), using a 7.5% acrylamide/0.375% bisacrylamide gel. Fluorography was carried out using Autofluor (National Diagnostics) according to the manufacturer's directions. [3H]leucine in either the absence (-) or the presence (+) of 10 ,ug of R6G per ml. After harvesting with immunoprecipitation buffer, the extracts were combined, immunoprecipitated, and electrophoresed.
RESULTS AND DISCUSSION
The gel was treated for fluorography and exposed to Kodak XAR-5 film for 6 days at -70'C. pMUT, migration position of the normal mutase precursor; MUT, position of the normal mature mutase subunit. and absence of R6G, an inhibitor of mitochondrial transport and processing (13) . As expected, labeled mature mutase subunit (MUT) is recovered from the control cell line (line 87) in the absence of R6G, and labeled mutase precursor (pMUT) is recovered in its presence. One of the mutant lines (505) has no immunoprecipitable newly synthesized mutase protein, with or without R6G. This is consistent with our previous data that this line had no steady-state crossreacting material (CRM) by radioimmunoassay (10) . Two of the mutant cell lines (588 and 663) show a pattern similar to that of the control, although with some difference in the amounts of labeled MUT and pMUT recovered. This indicates that, for these lines, the mutation causing mutase deficiency does not result in absent or aberrant mitochondrial processing. Line 663 had about 10% CRM by the steady-state assay (10) and has a similarly small amount of newly synthesized protein.
On the other hand, line 588 is one we have described as CRM negative by steady-state radioimmunoassay (10) . The detection of newly synthesized labeled protein suggests that the mutation in this line results in decreased long-term stability of the mutase protein. Finally, two lines (437 and 552) show aberrant patterns. Each produces two specifically immunoprecipitable MUT bands in the presence of R6G, consistent with the idea that each of the patients from whom the cells were derived were compound heterozygotes. In line 437, there are two proteins in the absence of R6G as well, one equal in size to the normal mature species and one several kilodaltons smaller. It seems likely that they are the products of proteolytic processing of the two species observed in the presence of R6G, although it is possible that only the upper precursor is cleaved, while the smaller remains unchanged in apparent size. This line had a very small amount of steadystate CRM (4% of control) (10) , in contrast to the relatively large amount of newly synthesized labeled protein apparent in Fig. 1 (lane 437, -) . More interestingly, however, line 552 generates the same two bands with and without R6G, indicating that neither of these mutase species can be processed by mitochondria. In addition, line 552 was CRMnegative by steady-state assay (10) , suggesting that these mutant proteins may be unstable when they cannot be imported properly. Table 1 summarizes the data on newly synthesized mutase protein from a number of experiments similar to Fig. 1 . Because of technical difficulties inherent in the cell-labeling protocol, no attempt was made to quantitate the amounts of labeled protein recovered. Twenty-one lines had been characterized previously as to type of mutase defect (mutC or mut') and amount of steady-state CRM (10) . Ten of these (3 mut-, 7 mut°), which had been shown previously to have detectable steady-state CRM, had amounts of newly synthesized mutase that ranged from approximately equivalent to the steady-state levels (3 mut-, 4 mut°) to considerably greater than steady-state (3 mut°). Surprisingly, ofthe 11 mut°l ines that had no detectable steady-state CRM, 5 had clearly demonstrable newly synthesized mutase protein in amounts ranging from barely detectable to almost half that of control. In each of these cases, the identity of the proteins as mutase was confirmed by precipitation in the presence of excess added purified human mutase and with control rabbit serum. The other 6 CRM-negative mut°lines had no demonstrable labeled mutase. Finally, among 27 lines not previously characterized according to mutant subgroup or steady-state CRM, only 4 were devoid of newly synthesized mutase. Several conclusions can be drawn from these data. First, the variation in the amount of newly synthesized mutase among the mutant lines confirms our basic hypothesis that methylmalonic acidemia due to mutase apoenzyme deficiency can result from a number of different mutations, each of which produces a unique effect on the synthesis, stability, or activity of the enzyme. This is further confirmed by the Newly synthesized mutase protein was determined by pulselabeling fibroblasts from a control and from patients with methylmalonic acidemia due to mutase apoenzyme deficiency in the absence of R6G; this was followed by immunoprecipitation and electrophoresis. Gels were routinely exposed 5-8 days at -70'C. *Taken from table 1, ref. 10. tEstimated by comparing by eye the intensity of the fluorographic image for a given line with that of the concurrently exposed control line. + + +, Approximately half the control; + +, moderately intense but less than half the control; +, detectable but much less than half the control; -, undetectable.
observation that two lines (437 and 552) synthesized two mutase proteins, each presumably under the control of a separate mutant allele. Two other probable compound heterozygotes with mutase deficiency have been described (14) . Second, the fact that only 10 lines of the 48 examined were unable to synthesize any immunorecognizable mutase protein suggests that mutase deficiency does not usually result from complete absence of the protein. On the other hand, our previous data that none of the 8 CRM-positive mut' lines had >40% as much mutase protein as controls (10), and our present observations that none of these lines appears to produce more than half as much newly synthesized mutase as control, suggest that null alleles may be present in many compound heterozygotes with mutase deficiency. One such mutant has been described, based on evidence from enzyme kinetics (14) .
Finally, the observation that 5 of 11 lines that were CRM-negative by the steady-state assay were able to synthesize some labeled mutase protein makes it clear that the absence of mutant protein, as detected by conventional immunoassay techniques, does not imply that the mutation results in the absence oftranslatable mRNA. Rather, in about half of the cases examined here, a missense mutation (or small deletion) apparently generates a protein that is so unstable in vivo that it cannot accumulate, even though its synthesis proceeds to some extent. A similar situation has been reported for two cystathionine synthase-deficient cell lines that were CRM-negative by a steady-state assay but that produced newly synthesized protein when pulse-labeled (12).
The conclusions generated by these observations are similar to those predicted by extension from the large body of information on variation and mutation in such well-studied proteins as the globins. Fig. 1 ). Of the 38 lines examined that had detectable newly synthesized mutase protein, only the 2 shown in Fig.   1 , lines 437 and 552, showed any differences from the control pattern (line 87).
To confirm that the proteins recovered from these mutant fibroblasts in the presence of R6G were the primary translation products, poly(A)+ RNA was prepared from each of these lines, along with the control, and used to direct in vitro translation. Fig. 2 shows the results after immunoprecipitation of the translation mixtures. The indicated products were specifically immunoprecipitated as before (not shown) and corresponded to those detected by pulse-labeling in the presence of R6G (Fig. 1) . Interestingly, although precise quantitation was not possible, the total amount of the translation products directed by RNA from line 437 appeared to be comparable to that from control, suggesting that the messages were present in near-normal amounts and could be efficiently translated. This is in contrast, however, to the results on the steady-state CRM in this line, which showed only 4% of control CRM (10) . Line 552 RNA generated considerably less product than control, suggesting either that there was less mRNA present, because of effects of the mutation on mRNA production or stability, or that the mRNA was inefficiently translated, again as an effect of the mutation. In either case, the recovery of some translatable RNA contrasts with our previous observation of no steadystate CRM in this line (10) .
The translation products from each of the RNAs were incubated with isolated rat liver mitochondria in an attempt to demonstrate whether these proteins could be recognized as precursors and transported and processed in vitro. The mutase precursor from the control line translation was taken up and converted to the mature mutase subunit as expected (data not shown). Both of the sets of mutant translation products were unstable when incubated with mitochondria, however, and no specific proteins could be recovered immunologically after the incubation. This result could simply be a reflection of the lability of these proteins already noted in intact fibroblasts.
Based on the data in Figs. 1 and 2 , it appears that line 437 has one allele that specifies a normal-sized protein and a second allele that produces one that is 3-4 kDa smaller, essentially the size of the leader peptide. The simplest explanation for the differences in the labeled proteins recovered in the presence and absence of R6G in Fig. 1 is that both primary translation products are processed by mitochondria in vivo to the corresponding mature subunits. Because we have shown for ornithine transcarbamoylase that a major portion of the leader peptide must be present to permit proper mitochondrial transport (4), it seems unlikely that the shorter protein results from a deletion that removes the aminoterminal leader peptide. Therefore, we would suggest that it represents either a carboxyl-terminal truncation because of a nonsense mutation or a small in-frame deletion within the mature subunit sequence.
Line 552, on the other hand, clearly carries a mutation (or mutations) that prevents normal mitochondrial processing of the primary translation products. This results (Fig. 1) in there being no difference in the sizes ofthe proteins recovered from this line in the presence or absence of R6G. Because the mutant proteins are considerably smaller than normal and are not processed, it seems likely that they are the result of deletions at the amino terminus that remove the usual translational start site, the leader peptide, and some of the mature sequence. A number of investigators have shown that leader peptides are required for mitochondrial transport and processing (1, 2). Therefore, the truncated mutant proteins synthesized by line 552 probably accumulate in the cytosol and are rapidly degraded. To our knowledge, a clear example of a natural human mutation that leads to aberrant mitochondrial transport has not been reported previously, although Ikeda et al. (5) have suggested that the mutation in one patient with isovaleryl-CoA dehydrogenase deficiency may result in somewhat reduced efficiency of mitochondrial processing of the mutant enzyme. The mutation in line 552 may shed additional light on the means by which leader peptides direct mitochondrial uptake once the mutation has been characterized at the structural level. In addition, it confirms our hypothesis that mutations affecting this transport system can be recognized in intact cells in culture and provides an impetus to our continuing search for other examples of this type.
